PCR-based co-detection of respiratory bacterial pathogens among hospitalized COVID-19 patients: Early-pandemic data from Golestan Province, Iran
A retrospective study of hospitalized COVID-19 patients in Golestan Province, Iran, found that bacterial DNA from various respiratory pathogens was frequently detected via PCR in upper-airway specimens, with *Pseudomonas aeruginosa* specifically associated with severe disease, though the findings likely reflect bacterial colonization rather than active co-infection due to methodological limitations.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a virus attacks the lungs, it does more than just cause fever and coughing; it can weaken the body's defenses, leaving the door open for other invaders. In the early days of the global pandemic caused by the SARS-CoV-2 virus, doctors faced a difficult puzzle: distinguishing between the viral pneumonia caused by the new coronavirus and a secondary bacterial infection that might be attacking at the same time. Both conditions can look identical on a scan and feel the same to a patient, yet they require different treatments. If a patient has a bacterial infection, antibiotics can save their life; if they do not, those same drugs are useless and can cause harm. Understanding how often these bacterial co-infections occurred, and which specific bacteria were involved, was critical for guiding care, especially for those who were most sick.
In the Golestan Province of Iran, a team of researchers set out to examine this question during the first wave of the pandemic, between June and November 2020. They focused on 254 patients who had been hospitalized with confirmed COVID-19. Instead of waiting for bacteria to grow in a culture dish—a process that can take days and often misses the target—the scientists used a highly sensitive molecular test called polymerase chain reaction, or PCR. This technique acts like a microscopic searchlight, capable of finding tiny fragments of bacterial DNA even when the bacteria are not alive or actively multiplying. The researchers swabbed the noses and throats of these patients and scanned for eight different types of respiratory bacteria known to cause trouble in the lungs.
The results revealed a complex picture. More than half of the hospitalized patients, specifically 60.6 percent, showed signs of bacterial DNA in their upper airways. This was a high number, suggesting that bacteria were frequently present alongside the virus. The most common bacteria found were Staphylococcus aureus, Streptococcus pneumoniae, and Stenotrophomonas maltophilia. However, the researchers were careful to explain what this high number actually meant. Because the test was done on swabs from the nose and throat, and because PCR is so sensitive that it can pick up dead bacteria or harmless colonization, these positive results did not necessarily mean every patient had an active, dangerous infection. It was possible that the bacteria were simply living in the nose without causing harm, or that the test was detecting remnants of bacteria that had been killed by antibiotics or the immune system.
Despite this caution, the study found a clear link between the severity of the illness and the presence of certain bacteria. When the researchers looked closely at the data, they discovered that patients with severe or critical COVID-19 were significantly more likely to have Pseudomonas aeruginosa detected in their samples compared to those with mild cases. This specific bacterium is often associated with hospital-acquired infections and can be particularly dangerous for people with weakened immune systems. The connection remained strong even after the researchers accounted for other factors like age and other health conditions. Conversely, the study found no significant link between the presence of bacteria and the patient's age, gender, or whether they ultimately survived, suggesting that the mere detection of bacterial DNA in the nose was not a reliable predictor of death on its own.
The findings also highlighted the challenges of diagnosing these infections during a crisis. The study noted that because the samples were taken at different times during the patients' hospital stays, it was impossible to tell if the bacteria were present when the patient first arrived or if they were acquired later while in the hospital. This uncertainty meant that the high detection rates likely reflected a mix of community-acquired bacteria and those picked up during hospitalization. The researchers emphasized that while their work provided a snapshot of what was happening in the early days of the pandemic in their region, it could not prove that the bacteria were causing the patients' conditions to worsen. To truly understand the role of these bacteria, future studies would need to look deeper into the lungs, use traditional culture methods to confirm living bacteria, and track exactly when patients were exposed to antibiotics.
Ultimately, this research served as a vital reminder that the human body during a viral pandemic is a complex ecosystem. While the virus was the primary threat, the presence of bacterial DNA in the airways of more than half of the hospitalized patients indicated that the landscape of infection was crowded and difficult to navigate. The study did not offer a simple rule for treating every patient, but it did provide essential data showing that severe illness was often accompanied by specific bacterial signatures. By mapping out these patterns, the researchers helped clarify that while bacteria were frequently present, distinguishing between a harmless passenger and a deadly co-infection remains one of the most difficult tasks in modern medicine.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.